CEACAM19 Inhibitors
CEACAM19 inhibitors encompass a variety of compounds that, through their action on specific signaling pathways, can indirectly inhibit the functional activity of CEACAM19. CEACAM19 is known to participate in cellular adhesion, a process that is integral to cell-cell interactions and tissue maintenance. The inhibition of kinases such as PDGFR and EGFR, which are central to the signaling cascades that ultimately regulate cell adhesion, can lead to a reduction in CEACAM19's role in these processes. For instance, drugs such as Imatinib, Sunitinib, and Nilotinib, which target PDGFR, can diminish the phosphorylation and activation of proteins that are associated with the cellular adhesion machinery, thereby inhibiting the functional activity of CEACAM19 in cell adhesion.
The compounds listed above target various signaling pathways and receptor tyrosine kinases that are intricately linked to cellular processes such as adhesion, proliferation, and growth-processes in which CEACAM19 is implicated. By inhibiting the activity of kinases like EGFR, PDGFR, and c-Kit, these chemicals can disrupt the downstream signaling required for CEACAM19 to carry out its role in cell adhesion. For example, Erlotinib and Gefitinib, which are selective EGFR inhibitors, can disrupt the EGFR-mediated cell signaling pathways crucial for the adhesion function of CEACAM19. Similarly, Lapatinib's ability to inhibit both EGFR and HER2/neu impacts the HER2/neu-associated signaling pathways, potentially reducing CEACAM19's involvement in cell-cell adhesion and signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor that also inhibits PDGFR and c-Kit. CEACAM19 is associated with cell adhesion; inhibition of PDGFR can reduce the phosphorylation of intracellular proteins that are crucial for cell adhesion, thereby inhibiting CEACAM19's adhesion functions. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits EGFR, a receptor tyrosine kinase. CEACAM19 is involved in EGFR-mediated cell signaling pathways that control cell adhesion. By inhibiting EGFR, Erlotinib can reduce the downstream signaling required for CEACAM19 to promote cell adhesion. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual inhibitor of EGFR and HER2/neu. As CEACAM19 can be involved in signaling pathways downstream of HER2/neu, inhibiting this pathway can lead to a reduction in the cell-cell adhesion and signaling roles of CEACAM19. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor targeting RAF, VEGFR, and PDGFR. As CEACAM19 is implicated in cell adhesion, inhibiting these kinases can impair the cell signaling that contributes to the adhesive properties linked with CEACAM19. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases including PDGFR. By inhibiting PDGFR, Sunitinib can decrease the phosphorylation of proteins involved in the adhesion process, thereby inhibiting CEACAM19's role in cell adhesion. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib selectively inhibits EGFR. Since CEACAM19 is involved in EGFR-mediated signaling, Gefitinib's inhibition of EGFR can disrupt the signaling pathways that influence the functional role of CEACAM19 in cell adhesion. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a tyrosine kinase inhibitor for RET, VEGFR, and EGFR. Inhibition of these kinases can lead to decreased cell surface receptor signaling, which is crucial for the adhesion function where CEACAM19 is involved. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases and BCR-ABL. Src kinases are involved in the regulation of adhesion molecules; thus, Dasatinib can reduce Src kinase activity, which is likely to inhibit CEACAM19's function in cell adhesion. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a selective BCR-ABL inhibitor that also inhibits PDGFR and c-Kit. By inhibiting PDGFR, Nilotinib can reduce the activation of cell adhesion pathways where CEACAM19 is implicated. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib is a multi-tyrosine kinase inhibitor that targets VEGFR, PDGFR, and c-Kit. By inhibiting PDGFR, Pazopanib can decrease the phosphorylation of proteins that modulate cell adhesion where CEACAM19 is active. | ||||||